Amivantamab (JNJ-61186372; RybrevantTM) is a fully humanized bsAb targeting EGFR and cMET and is the first approved therapeutic agent for NSCLC patients with EGFR exon 20 insertion (EGFR ex20ins) after failure of platinum-containing chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.